Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies

已完结 10 由 Luke 发布于 2026/1/29 13:48:16

DOI:10.1016/j.jaci.2025.09.028
作者：Ana Maria Giménez-Arnau MD, PhD ,?Robert Szalewski MD ,?Michihiro Hide MD, PhD ,?Vipul Jain MD ,?Abdallah Khemis MD ,?Mark Lebwohl MD ,?Martin Metz MD ,?Giselle Mosnaim MD ,?Michael Palumbo MD ,?Ekin
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundRemibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, demonstrated significant improvements in disease activity over placebo in the 24-week phase 3 REMIX studie

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SpringerIntramuscular and Intravenous AAV-Mediated Gene Delivery in Mouse Models.